Doctors track Real-Life results of leukemia drug in belarus
NCT ID NCT07288515
Summary
This study aims to understand how well the drug acalabrutinib works for treating chronic lymphocytic leukemia (CLL) in everyday medical practice in Belarus. Researchers will observe about 50 adult patients who have just started taking this medication and follow them for two years. The goal is to collect real-world information on how long patients stay on the drug, its safety, and its effectiveness outside of controlled clinical trials.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGMinsk, Belarus
Conditions
Explore the condition pages connected to this study.